Related Experiment Video
Updated: Oct 11, 2025
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.6K
Atezolizumab Treatment for Progressive Multifocal Leukoencephalopathy
Emerging Infectious Diseases
|December 2, 2021
Summary
Atezolizumab revived JC virus immunity in a progressive multifocal leukoencephalopathy patient, showing treatment response. However, immune reconstitution inflammatory syndrome and adverse events required corticosteroid treatment, leading to resistance.
Area of Science:
- Neuroimmunology
- Viral Immunology
- Oncoimmunology
Background:
- Progressive multifocal leukoencephalopathy (PML) is a rare, fatal demyelinating disease caused by the JC virus (JCV).
- JC virus reactivation occurs in immunocompromised individuals, often associated with natalizumab or other immunosuppressive therapies.
- Restoring JCV-specific immunity is a therapeutic goal for PML.
Observation:
- Atezolizumab, an immune checkpoint inhibitor, was administered to a patient with PML.
- The patient exhibited clinical, virologic, and radiologic improvements following atezolizumab treatment.
- Treatment led to the development of immune reconstitution inflammatory syndrome (IRIS) and severe immune-related adverse events.
Findings:
- Atezolizumab successfully reinvigorated JC virus immunity, leading to a positive treatment response.
- The patient experienced severe immune reconstitution inflammatory syndrome (IRIS) and immune-related adverse events.
- Corticosteroid treatment for IRIS and adverse events resulted in resistance to further therapy.
Implications:
- Atezolizumab may offer a potential therapeutic strategy for PML by restoring JCV immunity.
- IRIS and immune-related adverse events are significant complications that require careful management.
- Treatment resistance following immunosuppression for adverse events highlights the complexity of managing PML with immunotherapy.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
290
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
290
01:20Antiepileptic Drugs: Potassium Channel Activators
340
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
340
01:14Antiepileptic Drugs: Glutamate Antagonists
584
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
584
01:27Open Angle Glaucoma: Treatment
746
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
746
01:20Myasthenia Gravis: Overview and Treatment
2.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.1K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
242
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
242